# Tobramycin Delivered by Nebulized Sonic Aerosol for Chronic Rhinosinusitis Treatment of Cystic Fibrosis Patients

> **NCT02888730** · PHASE3 · TERMINATED · sponsor: **Virginie ESCABASSE** · enrollment: 86 (actual)

## Conditions studied

- Cystic Fibrosis
- Rhinosinusitis
- Lung Diseases

## Interventions

- **DRUG:** Tobramycin nebulized nasally
- **DRUG:** Physiologic serum nebulized nasally

## Key facts

- **NCT ID:** NCT02888730
- **Lead sponsor:** Virginie ESCABASSE
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-16
- **Primary completion:** 2017-05-16
- **Final completion:** 2019-07-08
- **Target enrollment:** 86 (ACTUAL)
- **Why stopped:** No suffisant recruitment
- **Last updated:** 2023-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02888730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02888730, "Tobramycin Delivered by Nebulized Sonic Aerosol for Chronic Rhinosinusitis Treatment of Cystic Fibrosis Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02888730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*